E‐cadherin expression is associated with somatostatin analogue response in acromegaly

Acromegaly is a rare disease resulting from hypersecretion of growth hormone (GH) and insulin‐like growth factor 1 (IGF1) typically caused by pituitary adenomas, which is associated with increased mortality and morbidity. Somatostatin analogues (SSAs) represent the primary medical therapy for acrome...

Full description

Saved in:
Bibliographic Details
Published in:Journal of cellular and molecular medicine 2019-05, Vol.23 (5), p.3088-3096
Main Authors: Venegas‐Moreno, Eva, Flores‐Martinez, Alvaro, Dios, Elena, Vazquez‐Borrego, Mari C., Ibañez‐Costa, Alejandro, Madrazo‐Atutxa, Ainara, Japón, Miguel A., Castaño, Justo P., Luque, Raúl M., Cano, David A., Soto‐Moreno, Alfonso
Format: Article
Language:English
Subjects:
acromegaly
Acromegaly - drug therapy
Acromegaly - genetics
Acromegaly - pathology
Adult
Biomarkers - metabolism
Biomarkers, Pharmacological - metabolism
Brain cancer
Cadherins - genetics
E‐cadherin
Female
Gene Expression Regulation - drug effects
Growth Hormone - genetics
Humans
Insulin-Like Growth Factor I - genetics
Male
Middle Aged
Original
Pituitary gland
Pituitary Neoplasms - drug therapy
Pituitary Neoplasms - genetics
Pituitary Neoplasms - pathology
Pituitary Neoplasms - surgery
pituitary tumour
Receptors, Somatostatin - genetics
Somatostatin - administration & dosage
Somatostatin - analogs & derivatives
somatostatin analogues
somatostatin receptor
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Acromegaly is a rare disease resulting from hypersecretion of growth hormone (GH) and insulin‐like growth factor 1 (IGF1) typically caused by pituitary adenomas, which is associated with increased mortality and morbidity. Somatostatin analogues (SSAs) represent the primary medical therapy for acromegaly and are currently used as first‐line treatment or as second‐line therapy after unsuccessful pituitary surgery. However, a considerable proportion of patients do not adequately respond to SSAs treatment, and therefore, there is an urgent need to identify biomarkers predictors of response to SSAs. The aim of this study was to examine E‐cadherin expression by immunohistochemistry in fifty‐five GH‐producing pituitary tumours and determine the potential association with response to SSAs as well as other clinical and histopathological features. Acromegaly patients with tumours expressing low E‐cadherin levels exhibit a worse response to SSAs. E‐cadherin levels are associated with GH‐producing tumour histological subtypes. Our results indicate that the immunohistochemical detection of E‐cadherin might be useful in categorizing acromegaly patients based on the response to SSAs.
ISSN:1582-1838
1582-4934
DOI:10.1111/jcmm.13851